{
    "nctId": "NCT03092635",
    "briefTitle": "AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy",
    "officialTitle": "Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 9,
    "primaryOutcomeMeasure": "AGE level reduction",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have ER+ breast cancer\n* Metastatic disease; protocol does allow for bone-only disease\n* Must be receiving endocrine therapy\n* Must have completed at last 2 months of current endocrine therapy prior to registration\n* Must have adequate hematologic, renal and hepatic function\n* Prior/concurrent radiation therapy is allowed\n* Prior chemotherapy is allowed, but last dose must have been at least 2 months prior to enrollment\n* May have diabetes, but must not be taking metformin\n* Must be able to swallow and retain oral medication\n* Performance status of 0-2\n* Treated stable brain metastases are allowed, as long as patient does not require steroids or anti-seizure medications\n* Must be informed of the investigational nature of this study and must have the ability to sign informed consent.\n\nExclusion Criteria:\n\n* Known allergy to grapes or grape seed\n* More than two prior endocrine therapy regimens for the treatment of metastatic ER+ breast cancer.\n* Concurrent use of restricted agents outlined in section 4.5.\n* History of alcohol abuse within 2 years of registration.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}